Pulmonary hypertension (PH) is a multifactorial chronic pulmonary disease. During the past decade, various pathophysiological pathways eventually leading to progressive pulmonary vascular remodelling have been detected...

Webinar presentations: Ardeschir Ghofrani (PRO) vs Hiromi Matsubara (CON) on Riociguat should be given to all CTEPH patients, regardless of timing of PEA/BPA, Systematic follow-up of patients following acute pulmonary embolism is associated with an increased incidence of CTEPH and less severe disease, Charlotte Durrington, Women and CTEPH: The special meaning of BPA, Alejandro Cruz-Utrilla, G protein-coupled receptor expression from single cell RNA sequencing in CTEPH, Gayathri Viswanathan, Study of the antifibrotic action of JAK inhibitors for the prevention and treatment of CTEPH, Andrei Karpov, Unilateral chronic thromboembolic pulmonary disease: Do they benefit from surgery? Farid Rashidi

Webinar presentations

• Looking beyond the hype: Applied AI and machine learning in translational medicine, Dennis Wang
• Computational network pharmacology in cardiovascular disease – leveraging big data, Joseph Loscalzo
• Utilizing artificial intelligence to screen and diagnose iPAH, David Kiely
• Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood, Sokratis Kariotis
• Transcriptomic characterization of Pulmonary arterial hypertension on pathway level, Yajing Ji 

• When should a PH patient be considered for lung transplant? John Granton 
• Atrial septum defect creation or mechanical support for end-stage PAH Erika Rosenzweig 
• Lung and Heart-lung Transplant in 2021 – how well do PAH patients do? Eugene Golts
• Pluripotent stem cell-based approaches and the future of artificial lungs Ulrich Martin
• Timing and extent of ventricular reverse remodelling after lung transplant for PH Ryan Tedford 

An article from the PVRI IDDI Emerging Technologies Working Group by Peter Fernandes

• MicroRNAs and IncRNAs in right heart hypertrophy and failure Francois Potus
• LncRNA as biomarkers/therapeutic agents for pulmonary diseases - prospective view Stephen Chen 
• Epigenomics in pulmonary vascular remodelling Soni Savai-Pullamsetti 
• Multiomic tools for single cell analysis Herbert Schiller
• Proteomics: From discovery research toward the clinic - novel AI perspectives? Christopher Rhodes 

Pulmonary hypertension (PH) is a frequent finding in advanced COPD. Usually pulmonary pressure is only mildly elevated, but a subgroup of patients develops severe PH, arbitrarily defined as mean pulmonary pressure (mPAP) ≥35 mmHg)...

• Role of notch1 in experimental pulmonary hypertension Ralph Schermuly
• Notch-BMPR interactions in endothelium in PAH Marlene Rabinovitch
• Notch3 is a driver and biomarker for PAH Patricia Thistlethwaite 
• Notch3 lineage and pulmonary vasculopathy Maya Kumar 

• A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH, Peter Dorfmüller
• Remnants of lost pulmonary vasculature may be re-engaged in PAH, Duncan Stewart
• Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs, David Systrom
• Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs, Roham Zamanian

• The right ventricle in HFpEF, Marco Guazzi
• Genetic aspects in group2 PH, Mark Toshner 
• Exercise haemodynamics in heart failure: what can we learn from invasive CPET? Gabor Kovacs 
• Systemic consequences and interorgan cross-talk in heart failure and PH, Stephan Rosenkranz
• The natriuretic peptide Clearance receptor selectively causes right ventricular dysfunction in a model of pulmonary hypertension and heart failure with preserved ejection fraction, Vineet Agrawal 
• N-Lysine methyltransferase Smyd2-mediated HIF-1A stabilization plays a protective role in RV hypertrophy, Swathi Veeroju